Page 128 - Genentech News Today

Solanezumab, a monoclonal antibody that binds to the monomeric or soluble form of amyloid-beta, is no better than placebo in slowing the progression of preclinical Alzheimers, results of a phase 3 trial show.

Positive data were announced from a phase 3 trial evaluating an investigational SC formulation of ocrelizumab in patients with MS.

An international consortium analyzes the cell-by-cell architecture of the placenta, intestine and kidneys, moving closer to achieving the dream of creating the first map of the entire organism

Along with the major trait of independence, vision is a projection of an entrepreneur’s mind where s/he breathes life into an opportunity A general definition of an entrepreneur is a person who identifies “opportunities” in an environment that have the potential to generate wealth by making

Initiating treatment within 6 months of the first symptoms of multiple sclerosis is linked to a 45% lower risk for disability years later.

Ann Lee-Karlon spent nearly two decades at Genentech and left in 2021 to join Altos Labs as its COO. Now she's the new CEO of a San Mateo-based biotech.

Imugene Ltd (ASX:IMU, OTC:IUGNF) has appointed two-decade veteran Dr Ron Weitzman as its interim chief medical officer, replacing Dr Giovanni Selvaggi. Dr...

/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase a science-driven and patient-centric exhibit at the 2023 American Association of Clinical...

"On Premise Patient Access Solution market size, share, top trends and future outlook", a new study published by OrbisResearch.comThe Worldwide On Pre

Marc Tessier-Lavigne was cleared of accusations of scientific fraud and misconduct. But the review said his work had “multiple problems” and “fell below customary standards of scientific rigor.”